FDA OKs Gilead's Remdesivir As First COVID-19 Treatment Despite WHO Findings
India, Oct. 23 -- The U.S. Food and Drug Administration (FDA) has gone ahead with the approval of antiviral drug remdesivir as first treatment for COVID-19, notwithstanding last week's findings by the World Health Organization (WHO) that the drug is not effective for COVID-19 treatment.
Thursday, Gilead Sciences announced that the FDA approved remdesivir, sold under the brand name Veklury, for the treatment of patients with coronavirus (COVID-19) requiring hospitalization.
Last week, interim results from the Solidarity Therapeutics Trial, coordinated by the WHO, had revealed that Ebola drug remdesivir appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.
The trial al...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.